Liraglutide shows promise in helping patients, even those without diabetes, lose weight says maker Novo Nordisk which is hoping for FDA approval. Both it and rival, Alli are being studied for their side effects.
A new class of diabetes drugs has shown promising results in a clinical trial conducted to help bring it to market. If approved, liraglutide would be the second GLP-1 diabetes medicine approved by the FDA for sale in the U.S. Byetta was the first.
Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery. We are committed to serving the public with honesty and integrity in these efforts.
On the Road
Major Medical
Protecting Your Family
In the Workplace
Motley Rice Ranked A Best Law Firm by U.S. News and World Report
Tampa Toddler Dies After Being Left In Vehicle
Burn Advocates Network Returns From Mission In Haiti
Update: Burn Advocates Network In Haiti
Burn Advocates Network In Haiti